VANDERBILT UNIVERSITY MEDICAL CENTER

A large-scale study of over 33,000 US veterans found that nicotinamide, a vitamin B3 derivative, reduced skin cancer risk by 14% overall and up to 54% when started after first diagnosis.

Ignite Proteomics and Vanderbilt University Medical Center have launched a one-year research collaboration to characterize protein-signaling pathways that help breast tumor cells evade immune system detection.

Avobis Bio completed primary analysis of the STOMP-II phase II trial for AVB-114, an implantable cell therapy targeting Crohn's perianal fistulas, and submitted a request for FDA RMAT designation.

iMDx's digital PCR-based GraftAssureIQ test demonstrated equivalent donor-derived cell-free DNA measurements compared to next-generation sequencing platforms in a head-to-head study of 96 kidney transplant recipients.

Bispecific antibodies mosunetuzumab and epcoritamab demonstrate low rates of high-grade cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in follicular lymphoma patients.

A single-center study at Vanderbilt University Medical Center found specialty pharmacists performed over 2,000 interventions across 741 neurology patients in just three months, with 98% of recommendations accepted by providers.

Climate change directly impacts neurological health through air pollution and extreme heat, with particulate matter (PM2.5) linked to increased risk of stroke, dementia, and neurodevelopmental conditions.

Clinical trial participation faces major barriers, with trial unavailability and lack of physician referrals identified as primary obstacles to patient enrollment in research studies.

Cortechs.ai and EDAP TMS SA achieved a milestone with the first-ever OnQ Prostate-assisted Focal One Robotic HIFU procedure performed at UCSF Prostate Center.

Current immunotherapy and TKI combinations have significantly improved survival in metastatic RCC over the past decade, though treatment advances have reached a plateau.